ArticleBMC gastroenterology2025
Treatment of patients with hyperthyroidism and liver failure: a retrospective cohort study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanisms and Prognostic Assessment Value of Thyroid Hormone in Liver Failure.Journal of clinical and translational hepatology · 2026Review
- Case Report: Hyperthyroidism induced liver failure with Wolff-Parkinson-White syndrome.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHyperthyroidism complicated by liver failure is associated with high mortality, and the optimal treatment strategy remains unclear. We aimed to compare the clinical characteristics of patients who received different treatments for hyperthyroidism and liver failure.
methodsThis retrospective cohort study included 137 patients diagnosed with hyperthyroidism and Liver failure between January 2013 and December 2022. The patients were treated with methimazole (MMI) plus artificial liver support system (ALSS), radioactive iodine (
resultsAfter propensity score matching, no significant differences in treatment efficacy were observed between MMI plus ALSS and MMI alone at discharge (P = 0.425), 12 weeks (P = 0.104), or 24 weeks (P = 0.104). There were also no significant differences in treatment efficacy between
conclusionsOur results suggest that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.